Bluejay Diagnostics Inc
NASDAQ:BJDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (3.6), the stock would be worth $22.38 (1 059% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | $1.93 |
0%
|
| 3-Year Average | 3.6 | $22.38 |
+1 059%
|
| 5-Year Average | 392.1 | $2 415.56 |
+125 058%
|
| Industry Average | 3.1 | $19.23 |
+896%
|
| Country Average | 2.5 | $15.48 |
+702%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Bluejay Diagnostics Inc
NASDAQ:BJDX
|
1.9m USD | 0.3 | -0.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 9.3 | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 3.1 | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 5.5 | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 2.1 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 3.6 | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 4.6 | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 2.2 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 28.2 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 1.7 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 5 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Bluejay Diagnostics Inc
Glance View
Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-11-10. The firm is engaged in the developing and marketing minimally invasive point of care (POC) diagnostics tests and devices that provide patients and providers with access to healthcare. The firm offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. The company focuses on offering solution to the infectious disease, inflammation, and oncology markets. The Company’s ALLEREYE diagnostic test (ALLEREYE) is a POC device that offers healthcare providers a solution for diagnosis of allergic conjunctivitis. The firm's product candidate includes Symphony IL-6 Sepis triage, Symphony IL-6 LDT market, Symphony IL-6 SEPSIS, Symphony hsTNT/I and NT-proBNP. The company is utilizing the platform for detection of sepsis, cancer and other diseases. The company is also developing biomarkers for detection of other diseases, such as cardiac ischemia and congestive heart failure.
